News

What are the cardiometabolic risks of polypharmacy with quetiapine and long-acting injectable paliperidone in patients with schizophrenia?

What is new in research on ADHD?

Updates from Day 2 at the National Academy of Sciences Conference on adult ADHD.

The color of the year is…

“This is the first study to assess the standalone drug effects of MM-120 in the absence of any psychotherapeutic intervention.”

Happy holidays from the Psychiatric Times family!

John A. Talbott, MD: More than just a community psychiatrist.

How can we help refugee youth engage in positive coping strategies and heal from their trauma?

Wishing you light this holiday season!

Check out these updates for the National Academy of Sciences Conference on adult ADHD, including new research, thoughtful discussions, and more!

Since 2006, STAR*D stands out as an icon guiding treatment decisions of major depressive disorder. But what if it is broken?

MAPS has submitted an NDA for MDMA-assisted therapy for patients with posttraumatic stress disorder.

These important findings on esketamine nasal spray as a treatment for young individuals with suicidal ideation were presented at the ACNP 2023 Annual Meeting. We interviewed the vice president and head of neuropsychiatry clinical development at Johnson & Johnson Innovative Medicine to learn more.

A eulogy for an entertainer.

Researchers performed a systematic review and meta-analysis of the effects of clozapine on cognitive function in patients with treatment-resistant schizophrenia.

With hate speech prevalent on college campuses and elsewhere, a psychiatrist ponders the psychiatric perspective and importance of therapeutic speech.

From adjunctive cariprazine for the treatment of major depressive disorder to a new app for prescribing antidepressants and antipsychotics, here are highlights from the week in Psychiatric Times.

What is new in research on cannabis?

As the trauma and grief of the Mideast war hit his own community , a psychiatrist helps promote healing.

Addressing shame in the treatment of OCD is a crucial component of the therapeutic process. Here’s what you need to know.

Researchers performed a double-blind, placebo-controlled pilot study of solriamfetol.

What have we learned—and what do we need to know—about the mental health implications of organizational and governmental dictatorships?

What neuromodulation can be used to specifically target nicotine users with schizophrenia? This research may tell us.

This ACNP 2023 Annual Meeting poster covered a 26-week study on cariprazine as an adjunctive treatment to antidepressants in patients with major depressive disorder.

The Psymatic Treatment Optimizer facilitates selecting agents ranked by adverse-effect profile with consideration of patient preference and tolerance.

Can the foundations of psychotherapy provide insight into today's conflict?

Neurosteroid therapeutics could be the solution to provide fast-acting treatment for mothers with postpartum depression.

Check out these brief summaries on cognitive impairment in schizophrenia from an excellent session at the ACNP 2023 Annual Meeting!

“This book is an original piece of psychiatric treatment didactics that has very useful characteristics for the benefit of well-motivated patients and conscientious mental health professionals.”